Fulgent Genetics (FLGT) Payables (2015 - 2026)

Fulgent Genetics has disclosed Payables across 12 years of filings, most recently posting $21.6 million for Q1 2026.

• Payables for Q1 2026 came in at $21.6 million, up 15.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.6 million (up 15.46% YoY), and the FY2025 annual result was $19.1 million, up 1.89% from the prior year.
• Payables came in at $21.6 million for Q1 2026 at Fulgent Genetics, up from $19.1 million in the prior quarter.
• In the past five years, Payables ranged from a high of $42.9 million in Q2 2022 to a low of $16.5 million in Q4 2023.
• The 5-year median for Payables is $20.0 million (2024), against an average of $22.7 million.
• Across the five-year window, Payables jumped 191.0% in 2022 and slumped 42.42% in 2023, its largest moves.
• Fulgent Genetics' Payables stood at $28.7 million in 2022, then plunged by 42.42% to $16.5 million in 2023, then climbed by 13.5% to $18.8 million in 2024, then rose by 1.89% to $19.1 million in 2025, then increased by 12.95% to $21.6 million in 2026.
• The last three Payables figures came in at $21.6 million (Q1 2026), $19.1 million (Q4 2025), and $18.6 million (Q3 2025), per Business Quant data.